`
`Cipla- Cipla- an Indian Generic Pharmaceutical Company
`
`Home > Corporate Information > At a Glance
`
`At a Glance
`
`PLAINTIFFS'
`TRIAL EXHIBIT
`PTX0379
`
`Cipla is a global pharmaceutical company whose goal is
`to ensure that no patient shall be denied access to high
`quality & affordable medicine and support.
`
`Mission:
`
`C ipla's mission is to be a leading ~!.!:!!aLll!i<!!ll!llt!~
`~=~wh ich uses technology and innovation to meet
`every day needs of all the patients .
`
`Incorporated
`1935
`
`Founder
`(1
`
`Dr. K.A. Hamied
`
`20,000+
`
`USD 1.78 Billion
`
`Dr. Y.K. Hamied
`
`Non(cid:173)
`Executive
`Vice-
`
`Mr. M.K. Hamied
`
`http://www.cipla.com/en/corporate-informationlat-a-glance.html
`
`1/3
`
`Registered Office
`
`MEDA APTX03503148
`
`PTX0379-00001
`
`1
`
`CIP2069
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`
`
`6/28/2016
`
`Cipla- Cipla- an Indian Generic Pharmaceutical Company
`
`Cipla Limited, Cipla House, Peninsula Business
`Park,
`Ganpatrao Kadam Marg, Lower Parel, Mumbai
`400 013
`
`Listing
`Equity Shares: BSE Limited and National Stock
`Exchange of India Limited
`Global Depository Receipts: Luxembourg
`Stock Exchange
`
`Highlig
`
`Continuous innovation in R & D w ith 35+
`world firsts.
`
`Over 1,000 products across various
`therapeutic categories, with 60+ dosage
`forms.
`
`Presence in over 1 00 countries
`
`US FDA , WHO-Geneva, MHRA-UK, TGA(cid:173)
`Australia, SUKL-Siovak Republic, APVMA(cid:173)
`Australia, MCC-South Africa, PIC-Germany,
`Danish Medical Agency, ANVISA-Braz il,
`INVIMA- Colombia, NDA-Uganda, Department of
`Health-Canada and MOH-Saudi Arabia, among
`others
`
`http://www.cipla.com/en/corporate-information/at-a-glance.html
`
`213
`
`Mumbai Central Office: +91 22 23082891 , +91
`22 23095521
`
`MEDA APTX03503149
`
`PTX0379-00002
`
`2
`
`
`
`6/28/2016
`
`Cipla- Cipla- an Indian Generic Pharmaceutical Company
`
`Peninsula Business Park Office: +91 22
`24826000, +91 22 24826701, +91 22 24826300
`
`R&D
`
`THEf~APIES
`
`CORPOf~ATE
`INFOF:ZMATION
`
`At a Glance
`
`Board of Directors
`
`Partnership
`
`Code of Conduct
`
`Quality
`
`Plants & Capacities
`
`Business
`
`Units
`
`New Ventures
`
`Leader in Drug
`Delivery
`
`Formulation
`Development
`
`API
`Development
`
`Regulatory
`
`Platform
`
`CSR
`
`Palliative Care
`
`Cardiovascular Children's
`Health
`
`Dermatology
`and
`Cosmetology
`
`Diabetes
`
`HIV/AIDS
`
`Hepatitis
`
`Malaria
`
`Infectious
`Diseases &
`Critical Care
`
`Neurosciences
`
`INVESTOR
`INFORMATION
`
`Financial Results
`
`Annual Report and
`Chairman's Speech
`
`Conference Call Transcripts
`
`Shareholder Information
`
`Unclaimed Dividend
`
`Women's
`Health
`
`Devices
`
`www.act-c.in
`
`www. breathefree. com
`
`Privacy Policy Disclaimer Contact Us
`
`Site Map Caution Notice- "Recruitment
`
`Site by a M.AGHON'\TBWA
`
`Fraud"
`
`©
`
`20 16
`
`Inc. All
`
`reserved
`
`http://www.cipla.com/en/corporate-information/at-a-glance.html
`
`313
`
`MEDA APTX03503150
`
`PTX0379-00003
`
`3
`
`